Alnylam Pharmaceuticals (ALNY) Free Cash Flow (2009 - 2026)

Alnylam Pharmaceuticals' Free Cash Flow history runs 18 years deep, the most recent figure standing at $48.7 million for Q1 2026.

• Quarterly Free Cash Flow rose 137.65% year-over-year to $48.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $643.3 million (up 830.12% YoY) and the FY2025 annual result came in at $465.4 million, up 1192.73% from the prior year.
• Free Cash Flow was $48.7 million for Q1 2026 at Alnylam Pharmaceuticals, down from $114.5 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $342.3 million in Q3 2023 and bottomed at -$197.9 million in Q4 2022.
• A 5-year average of -$2.4 million and a median of -$74.9 million in 2023 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2024 — Free Cash Flow slumped 880.0% — and 2025, when it surged 1629.56%.
• Alnylam Pharmaceuticals' Free Cash Flow stood at -$197.9 million in 2022, then jumped by 106.72% to $13.3 million in 2023, then slumped by 880.0% to -$103.8 million in 2024, then jumped by 210.32% to $114.5 million in 2025, then sank by 57.48% to $48.7 million in 2026.
• Business Quant data shows ALNY's Free Cash Flow at $48.7 million in Q1 2026, $114.5 million in Q4 2025, and $338.8 million in Q3 2025.